- Home
- GDS vs XENE Comparison
GDS vs XENE Comparison
Compare GDS & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDS
- XENE
- Stock Information
- Founded
- GDS 2001
- XENE 1996
- Country
- GDS China
- XENE Canada
- Employees
- GDS N/A
- XENE N/A
- Industry
- GDS Computer Software: Programming Data Processing
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- GDS Technology
- XENE Health Care
- Exchange
- GDS Nasdaq
- XENE Nasdaq
- Market Cap
- GDS 3.8B
- XENE 3.3B
- IPO Year
- GDS 2016
- XENE 2014
- Fundamental
- Price
- GDS $19.80
- XENE $38.63
- Analyst Decision
- GDS Buy
- XENE Strong Buy
- Analyst Count
- GDS 3
- XENE 9
- Target Price
- GDS $18.47
- XENE $56.67
- AVG Volume (30 Days)
- GDS 886.2K
- XENE 418.4K
- Earning Date
- GDS 11-19-2024
- XENE 11-12-2024
- Dividend Yield
- GDS N/A
- XENE N/A
- EPS Growth
- GDS N/A
- XENE N/A
- EPS
- GDS N/A
- XENE N/A
- Revenue
- GDS $1,564,750,016.00
- XENE N/A
- Revenue This Year
- GDS $18.06
- XENE N/A
- Revenue Next Year
- GDS $17.32
- XENE $1,599.99
- P/E Ratio
- GDS N/A
- XENE N/A
- Revenue Growth
- GDS 11.95
- XENE N/A
- 52 Week Low
- GDS $5.01
- XENE $35.53
- 52 Week High
- GDS $24.74
- XENE $50.99
- Technical
- Relative Strength Index (RSI)
- GDS 46.41
- XENE 39.23
- Support Level
- GDS $20.39
- XENE $37.52
- Resistance Level
- GDS $20.97
- XENE $41.62
- Average True Range (ATR)
- GDS 0.81
- XENE 1.66
- MACD
- GDS -0.06
- XENE -0.34
- Stochastic Oscillator
- GDS 22.65
- XENE 18.94
About GDS GDS Holdings Limited ADS
GDS Holdings started as an IT service provider in 2001 then moved to the data center business with its first self-developed data center opening in 2010. The company now develops and operates data centers in China and also builds, operates and transfers data centers for other clients. It offers colocation and managed services and mainly targets hyperscale cloud service customers who take large areas of its data centers or even whole data centers under long-term contracts. It has aggressively raised capital over the past four years for expansion. Its data centers are located predominantly in and around the Tier 1 cities in China and it has also started an expanding into Southeast Asia. GDS listed on the Nasdaq in 2016 and completed a secondary listing in Hong Kong in 2020.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.